Show simple item record

dc.contributor.authorDolan, Eimear B.
dc.contributor.authorKovarova, Lenka
dc.contributor.authorO'Neill, Hugh
dc.contributor.authorPravda, Martin
dc.contributor.authorSulakova, Romana
dc.contributor.authorScigalkova, Ivana
dc.contributor.authorVelebny, Vladimir
dc.contributor.authorDaro, Dorothee
dc.contributor.authorBraun, Nathalie
dc.contributor.authorCooney, Gerard M .
dc.contributor.authorBellavia, Gabriella
dc.contributor.authorStraino, Stefania
dc.contributor.authorCavanagh, Brenton L.
dc.contributor.authorFlanagan, Aiden
dc.contributor.authorKelly, Helena M.
dc.contributor.authorKelly, Helena M.
dc.contributor.authorDuffy, Garry P.
dc.contributor.authorMurphy, Bruce P.
dc.identifier.citationDolan, Eimear B, Kovarova, Lenka, O'Neill, Hugh, Pravda, Martin, Sulakova, Romana, Scigalkova, Ivana, Velebny, Vladimir, Daro, Dorothee, Braun, Nathalie, Cooney, Gerard M., Bellavia, Gabriella, Straino, Stefania, Cavanagh, Brenton L., Flanagan, Aiden, Kelly, Helena M., Duffy, Garry P., Murphy, Bruce P. (2018). Advanced Material Catheter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels. Journal of Biomaterials Applications, 33(5), 681-692. doi: 10.1177/0885328218805878en_IE
dc.description.abstractInjectable hydrogels that aim to mechanically stabilise the weakened left ventricle wall to restore cardiac function or to deliver stem cells in cardiac regenerative therapy have shown promising data. However, the clinical translation of hydrogel-based therapies has been limited due to difficulties injecting them through catheters. We have engineered a novel catheter, Advanced Materials Catheter (AMCath), that overcomes translational hurdles associated with delivering fast-gelling covalently cross-linked hyaluronic acid hydrogels to the myocardium. We developed an experimental technique to measure the force required to inject such hydrogels and determined the mechanical/viscoelastic properties of the resulting hydrogels. The preliminary in vivo feasibility of delivering fast-gelling hydrogels through AMCath was demonstrated by accessing the porcine left ventricle and showing that the hydrogel was retained in the myocardium post-injection (three 200 μL injections delivered, 192, 204 and 183 μL measured). However, the mechanical properties of the hydrogels were reduced by passage through AMCath (≤20.62% reduction). We have also shown AMCath can be used to deliver cardiopoietic adipose-derived stem cell-loaded hydrogels without compromising the viability (80% viability) of the cells in vitro. Therefore, we show that hydrogel/catheter compatibility issues can be overcome as we have demonstrated the minimally invasive delivery of a fast-gelling covalently cross-linked hydrogel to the beating myocardium.en_IE
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AMCARE consortium (FP7/2007-2013) under Grant Agreement No.604531.en_IE
dc.publisherSAGE Publicationsen_IE
dc.relation.ispartofJournal Of Biomaterials Applicationsen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjecthyaluronic aciden_IE
dc.subjectmyocardial infarctionen_IE
dc.subjectminimally invasive deliveryen_IE
dc.titleAdvanced Material Catheter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogelsen_IE
dc.contributor.funderSeventh Framework Programmeen_IE
dc.local.contactEimear Dolan, Biomedical Engineering 3031, College Of Engineering & Informa, Nui Galway. Email:
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::NMP/604531/EU/Advanced Materials for Cardiac Regeneration (AMCARE)/AMCAREen_IE

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland